GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Volatility

ALX Oncology Holdings (ALX Oncology Holdings) Volatility

: 115.65% (As of Today)
View and export this data going back to 2020. Start your Free Trial

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-04-19), ALX Oncology Holdings's Volatility is 115.65%.


Competitive Comparison

For the Biotechnology subindustry, ALX Oncology Holdings's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings Volatility Distribution

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Volatility distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Volatility falls into.



ALX Oncology Holdings  (NAS:ALXO) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ALX Oncology Holdings  (NAS:ALXO) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


ALX Oncology Holdings Volatility Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia officer: Chief Financial Officer ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph officer: Chief Medical Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S director, 10 percent owner, other: Executive Chairman 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani director 3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke officer: VP Fin & Chief Acct Officer C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538

ALX Oncology Holdings (ALX Oncology Holdings) Headlines

From GuruFocus

ALX Oncology Realigns Executive Leadership Team

By Marketwired 09-06-2023

ALX Oncology Announces Upcoming Investor Conference Participation

By Value_Insider Value_Insider 11-02-2022

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023